Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/17449
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation |
Author: | Davey, M. Teubner, D. |
Citation: | Annals of Emergency Medicine, 2005; 45(4):347-353 |
Publisher: | Mosby Inc |
Issue Date: | 2005 |
ISSN: | 0196-0644 1097-6760 |
Statement of Responsibility: | Davey, Michael John ; Teubner, David |
Abstract: | <h4>Study objectives</h4>We examine the safety and efficacy of magnesium sulfate infusion, in addition to usual care, for acute rate reduction in patients with atrial fibrillation and a rapid ventricular response rate.<h4>Methods</h4>This was a prospective, randomized, double-blind, placebo-controlled trial of intravenous magnesium sulfate in adult emergency department patients with rapid atrial fibrillation. Study solutions were given in addition to any therapy the treating physician would normally consider appropriate, including the use of standard rate-reduction agents. Patients received either 20 mEq (2.5 g, 10 mmol) magnesium sulfate over a 20-minute period, followed by 20 mEq (2.5 g, 10 mmol) over a 2-hour period intravenously, or placebo.<h4>Results</h4>One hundred ninety-nine patients were randomized, 102 to receive magnesium sulfate and 97 to receive placebo. The antiarrhythmic drug most commonly used by treating physicians was digoxin. Magnesium sulfate was more likely than placebo to achieve a pulse rate of less than 100 beats/min (63 [65%] of 97 versus 32 [34%] of 93, relative risk [RR] 1.89; 95% confidence interval [CI] 1.38 to 2.59; P <.0001) and more likely to convert to sinus rhythm (25 [27%] of 94 patients versus 11 [12%] of 91 patients; RR 2.20; 95% CI 1.15 to 4.21; P =.01). Comparative mean pulse rate reductions in the magnesium sulfate group did not reach predetermined clinical significance levels (> or =15 beats/min reduction) at any of the measured time points. Magnesium sulfate was more likely to be associated with an adverse event (14 [15%] of 95 patients versus 5 [5%] of 92 patients; RR 2.71; 95% CI 1.02 to 7.23; P =.04).<h4>Conclusion</h4>Magnesium sulfate, when used to supplement other standard rate-reduction therapies, enhances rate reduction and conversion to sinus rhythm in patients with rapid atrial fibrillation. |
Keywords: | Atrioventricular Node Heart Ventricles Humans Atrial Fibrillation Magnesium Sulfate Anti-Arrhythmia Agents Drug Therapy, Combination Double-Blind Method Heart Rate Aged Aged, 80 and over Middle Aged Emergency Service, Hospital Female Male |
DOI: | 10.1016/j.annemergmed.2004.09.013 |
Published version: | http://dx.doi.org/10.1016/j.annemergmed.2004.09.013 |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.